ABSTRACT
Objective:To investigate the effect of vasoactive intestinal peptide on IL-1β expression after corneal alkali burn.Methods:27 healthy adult female Wistar rats were randomly divided into group A(normal blank control group),group B(alkali burn treated with saline group),and group C (alkali burn treated with vasoactive intestinal peptide group).Group A were not processed.Group B,C were made right eyes′moderate corneal alkali burn models.After inducing burn,group B and group C were followed respectively by 0.9% saline and 0.25 g/L vasoactive intestinal peptide eye drops,4 times per day.The corneal epithelial healing rates were calculated by measuring the corneal staining area by methylene blue staining at 3 d,7 d and 14 d after inducing burn.At 3 d,7 d and 21 d,the corneal tissues were removed and divided into two equal parts.The corneal tissues were observed by staining,and the expression of IL-1β were detected by immunohistochemistry.Results:The healing rates of corneal epithelium in group C were greater than those in group B at 7 d and 14 d(P<0.05).The mean optical density of IL-1β was measured by immunohistochem-istry.The mean optical density in group B and group C at 3 d were(1.62 ± 0.96) ×10-2,(0.98 ± 0.45) ×10-2,respectively,which at 7 d were (1.42 ± 0.62) ×10-2,(0.71 ± 0.22) ×10-2,respectively,which at 21 d were(0.37 ± 0.24) ×10-2,(0.13 ± 0.16) × 10-2,respectively.The mean optical density of corneal IL-1β in group C were lower than those in group B(P<0.05).Conclusion:Va-soactive intestinal peptide can decrease the expression of IL-1β after corneal alkali burn,down-regulate the level of immune stress, reduce the inflammatory reaction and promote the recovery of cornea after alkali burn.
ABSTRACT
Objective To observe the clinical effects of individualized compre hensive treatment on dry eye disease secondary to chronic graft-versus-host disease.Methods A retrospective analysis was conducted on 19 patients (38 eyes) with dry eye disease associated with chronic graft-versus-host disease from March 2013 to November 2016 after treatment of hematopoietic stem cell transplantation,and the individualized comprehensive treatment including artificial tears,deproteinized calf blood extract eye gel,fibroblast growth factor eye gel and 1 g · L-1 fluorometholone eye drops were performed according to the severity of dry eye disease.Then slit lamp examination,the score on symptoms of dry eye,corneal fluorescein staining,tear break-up time (BUT) assay and Schirmer I test (SIT) were performed,and visual acuity was examined before and after treatment.Then,the changes of symptoms and signs of dry eye were observed completely before treatment and 2 months after treatment.Results The scores on partial symptoms of dry eye,including sensations of dryness,foreign mat ter,burning,pain,ocular hyperemia before and after treatment were 2.72 + 0.78 vs.1.68 + 0.82,2.58 + 0.89 vs.1.62 + 0.72,2.46 + 0.64 vs.1.57 + 0.59,2.27 + 0.54 vs.1.44 + 0.62,2.54 +0.66 vs.2.09 +0.58 respectively,presenting obviously improvement in these sensa tions (all P ＜0.05),while postoperative asthenopia and photophobia were slightly ameliorated,without statistical significance (P ＞ 0.05).Furthermore,visual acuity improved after treatment,and the difference was statistically siguificant;and there was significant difference in the score of corneal fluorescein staining between before treatment (8.6 + 2.4) to after treatment (2.2 + 1.6) (all P ＜0.05),but there was no significant difference in the score of BUT and SIT before and after treatment (all P ＞ 0.05).Conclusion The individual comprehensive medication can improve the subjective symptoms and signs of dry eye disease secondary to chronic graft-versus-host disease after hematopoi etic stem cell transplantation,and more importantly,ameliorate visual acuity.
ABSTRACT
Objective To observe the clinical effects of individualized compre hensive treatment on dry eye disease secondary to chronic graft-versus-host disease.Methods A retrospective analysis was conducted on 19 patients (38 eyes) with dry eye disease associated with chronic graft-versus-host disease from March 2013 to November 2016 after treatment of hematopoietic stem cell transplantation,and the individualized comprehensive treatment including artificial tears,deproteinized calf blood extract eye gel,fibroblast growth factor eye gel and 1 g · L-1 fluorometholone eye drops were performed according to the severity of dry eye disease.Then slit lamp examination,the score on symptoms of dry eye,corneal fluorescein staining,tear break-up time (BUT) assay and Schirmer I test (SIT) were performed,and visual acuity was examined before and after treatment.Then,the changes of symptoms and signs of dry eye were observed completely before treatment and 2 months after treatment.Results The scores on partial symptoms of dry eye,including sensations of dryness,foreign mat ter,burning,pain,ocular hyperemia before and after treatment were 2.72 + 0.78 vs.1.68 + 0.82,2.58 + 0.89 vs.1.62 + 0.72,2.46 + 0.64 vs.1.57 + 0.59,2.27 + 0.54 vs.1.44 + 0.62,2.54 +0.66 vs.2.09 +0.58 respectively,presenting obviously improvement in these sensa tions (all P ＜0.05),while postoperative asthenopia and photophobia were slightly ameliorated,without statistical significance (P ＞ 0.05).Furthermore,visual acuity improved after treatment,and the difference was statistically siguificant;and there was significant difference in the score of corneal fluorescein staining between before treatment (8.6 + 2.4) to after treatment (2.2 + 1.6) (all P ＜0.05),but there was no significant difference in the score of BUT and SIT before and after treatment (all P ＞ 0.05).Conclusion The individual comprehensive medication can improve the subjective symptoms and signs of dry eye disease secondary to chronic graft-versus-host disease after hematopoi etic stem cell transplantation,and more importantly,ameliorate visual acuity.